We present an analysis of this treatment protocol in 40 con- 
From March 1992 to February 1995, 40 patients from 11 French and Belgian Hematology departments were included in this study. All of them had previously untreated ALL and were aged 55 years or older. Patients with a poor performance Introduction status (ECOG 3-4) or with another concomitant malignant condition or with a poor cardiac function preventing the use Only few reports specifically devoted to acute lymphoblastic of anthracyclines as assessed clinically or by ventricular ejecleukemia (ALL) in the elderly are available, [1] [2] [3] [4] [5] [6] [7] probably tion fraction measurement were not eligible. because the condition is uncommon. Although heterogeneous with regard to population characteristics, these studies consistently report poor median survival ranging from 3 1 to 10
Immunophenotypic classification months 5 with a high death rate of up to 50%, during induction therapy. 8 Moreover, shorter median remissions (12 months) Classification of ALL according to immunophenotype was as are obtained in older adults than in younger patients (24 follows: B-ALL (CD19 + or CD20 + , surface immunoglobulin months) treated according to similar protocols. 5 +ve), Pre B-ALL (CD19 + or CD20 + , CD10 − ), common ALL In 1992, the French Group for Treatment of Adult ALL (CD19 + or CD20 + , CD10 + ), T-ALL (CD2 + or CD3 + ). initiated a study aimed at improving the prognosis of ALL in older patients. Induction therapy was derived from the young adult protocol LALA87 9 with chemotherapy administered at Treatment lower dose and tailored according to the response assessed on day 15. In addition, the feasibility of maintenance with The treatment scheme is presented in Figure 1 . Compared interferon (IFN) combined with chemotherapy was assessed.
with the LALA87 protocol used by us in younger adults, its The introduction of IFN in the treatment of ALL is supported main characteristics are: lower dose of chemotherapy, prednisone administered on alternate day, number of courses of anthracyclines tailored according to response as assessed by Two additional injections of daunorubicin were administered Cranial irradiation was performed only in patients with central in nine of the latter 15 patients, as stated in the treatment pronervous system (CNS) leukemic involvement. IFN was introtocol, while in six patients, the two courses of daunorubicin duced during maintenance, in addition to methotrexate and were omitted because of their poor condition. 6-mercaptopurine.
Out of the 34 complete responders, 32 patients received the scheduled consolidation therapy (one patient with a normal bone marrow died before consolidation was started and another one was felt unfit to proceed with consolidation treatment). Five patients relapsed during the consolidation Assessment of response phase.
Thus, 27 patients were alive and in CR after consolidation therapy. Twenty-five proceeded with maintenance treatment Complete response definition was derived from the CALGB's criteria: bone marrow with Ͻ5% blast cells, neutrophil count as stated in the protocol: one patient refused treatment with IFN while IFN was not administered in another patient Ͼ1 × 10 9 /l, platelet count Ͼ100 × 10 9 /l for at least 30 days.
17
Relapse was defined as the appearance of leukemic cells in because of psychiatric disorder. Relapse occurred in 18 patients during maintenance therapy 81-761 days after IFN the bone marrow (Ͼ5%) and/or reappearance of clinical and hematological evidence of disease.
was started (median 237 days). Toxicity from induction and consolidation treatment reductions were mainly due to regimen-induced hematologic toxicity. Three patients died early from treatment-related infectious complications: the first during induction treatment, another one died during the consolidation phase after failing inducOverall survival and disease-free survival tion, while an additional patient with a normal bone marrow died shortly after completing induction therapy. During induc-
The median survival of the whole group was 434 days and tion, neutropenia (neutrophil count Ͻ0.5 × 10 9 /l) lasted from the median DFS was 427 days (Figures 3 and 4) . In this small 0 to 57 days (median: 20 days) while a thrombocytopenia cohort, no survival difference could be demonstrated accord-Ͻ50 × 10 9 /l was recorded during 0 to 60 days (median 15 ing to sex, age (Ͼ70 vs Ͻ70 years), anemia, leukocyte count, days). Growth factors (G-CSF) were administered in only two platelet count, normal vs abnormal chromosome analysis, patients. Aplasia from consolidation therapy was mild with presence or absence of organomegaly. In addition, survival both neutropenia Ͻ0.5 × 10 9 /l and thrombocytopenia did not correlate with day 15 clearance of bone marrow Ͻ50 × 10 9 /l lasting 0-17 days (median: 0 ing the cutoff value of day 15 blast cell count from 20 to 5% severe anorexia, unacceptable hemototoxicity and mood disas recommended by Sebban et al 19 also failed to distinguish orders with anorexia developed in four, one and two patients, patients with a favorable outcome (median survival 364 vs respectively. In addition, IFN was withheld in one patient who 543 days in 16 patients with Ͻ5% blast cells and in 20 developed hemiplegia, possibly unrelated to therapy, 10 days patients with Ͼ5% blast cells, respectively, P = 0.3), again after starting IFN. Effectively provided doses, expressed as a with no impact on CR rates (14 CR in 16 patients with Ͻ5% percentage of the theoretical dose, are reported in Figure 2 .
bone marrow blast cells vs 16 CR in 20 patients with a blast On the average, three quarters of the theoretical doses of both cell count Ͼ5%). The median survival of the nine patients IFN and chemotherapy could be administered. Dose who were administered two additional courses of daunorubicin because of day 15 bone marrow infiltration with Ͼ20% blast cells was 262 days, vs 425 days in the 21 patients with Ͻ20% blast cells (P = 0.1). The median survival of the six patients who were felt unfit for receiving two additional injections of daunorubicin was 740 days (P = 0.1 compared with the nine patients given additional daunorubicin). Relapse occurred in 23 patients, including 16 bone marrow relapses, five CNS relapses and two CNS associated with bone marrow relapses. Two-year overall survival and DFS were 20 and 16%, respectively. in elderly people with ALL and to assess the feasibility of therapy with IFN during maintenance. With regard to outcome, Table 2 compares our data with those previously reported in patients accrued in treatment protocols. Thus, populationbased studies were not taken into account since, in such studies, all patients, including those not given chemotherapy, are included, which results in poor overall survival rates compared with survivals obtained in the setting of treatment protocols. In addition, patients aged 60 years and older are shown separately, as only patients aged 60 years or older were included in most other studies. Although comparisons should be interpreted with great caution, data from Table 2 suggest that more complete responses could be achieved in our patients with less toxic deaths which translated into longer overall survival. unmodified in older patients result in prohibitive mortality. 8 On the other hand, when induction treatment is oversimplified, (eg prednisone-vincristine), toxicity is mild but efficacy treated according to the LALA87 protocol was 18 months vs is also very modest. 4, 6 In this study, we elected to apply an 14 months in the present study 9 while 3-year overall survival intermediate treatment policy: elderly patients were adminiswas 36% compared with 10% in older adults. The reasons for tered all the drugs used by our group in younger adults but a better survival in younger adults with ALL are not clearly doses were lowered. In addition, treatment was tailored understood. A high leukocyte count, CNS involvement, organaccording to response as assessed by bone marow study at omegaly, which are poor prognosis characteristics, were not mid-treatment which may have contributed to improving encountered more frequently in elderly patients. On the conoverall results. Recent data suggest that in adults with ALL, trary, the leukocyte count was lower in our patients compared day 15 marrow is predictive both for response and for surto younger adults. T cell ALL comprises 20-25% of adult ALL vival. 19 Using the same cutoff of 5% blast cells in day 15 bone and has been associated with a favourable prognosis. 8 Relamarrow specimens we could not confirm the prognostic value tively few patients suffered T-ALL in his cohort (9%), which of day 15 bone marrow findings in this relatively small cohort. might have adversely affected their prognosis. A relatively low
Discussion
We suggest that the comparatively encouraging outcome frequency of T-ALL in older patients has been reported by observed in our patients results from treatment-related characothers: 0/15, 1 2/41, 2 0/9, 3 2/26. 4 However, the poor prognosis teristics, although, outside the setting of a randomized trial, of ALL in older persons cannot be accounted for only by a alternative explanations, including study population characlow incidence of T-ALL as the prognosis of ALL in the elderly teristics, cannot be ruled out. Of note, our patients did not is poor, even when compared to the prognosis of B-ALL in differ from those treated elsewhere with respect to age and to younger patients. Philadelphia chromosome has been consistthe proportion of Ph-positive ALL, two main determinants of ently associated with a poor outcome in ALL. The incidence outcome in ALL, while, conversely, excluding from our study of Ph-positive ALL increases with age but seems to stabilize patients with a poor cardiac function or performance status, beyond the age of 60. 20 This was also our experience: and with another simultaneous malignancy may have resulted although more elderly patients presented with Ph-positive leuin selecting a subset of patients with favorable prognostic feakemia (31%) compared to younger adults treated according tures compared to studies presented in Table 2 . to the LALA87 protocol (20%), the difference was not signifiHematotoxicity from consolidation therapy in this study was cant and could not account on its own for the poor prognosis very mild. Thus, although the therapeutic potential of consoliof ALL in the elderly. dation treatment remains controversial, higher doses of The main purposes of our study were to improve outcome chemotherapy could be safely used in future protocols. Survival could be further increased by intensifying CNS prophylaxis as an unduly high number of CNS relapses (7/23), reasonably ascribable to our reduced CNS therapy, occurred in this cohort. With regard to the feasibility of using IFN and chemotherapy during maintenance therapy, most elderly patients could tolerate IFN provided the dose was reduced to three quarters of the planned dose. This study was not designed to assess the efficacy of IFN during maintenance. However, similar to previously reported cohorts, few patients if any will be cured which suggests that IFN is unlikely to improve survival dramatically. Finally, we cannot exclude that reducing the doses of methotrexate and 6-mercaptopurine may have offset the anti-leukemic effect of IFN, if any.
In conclusion, although prognosis in older patients with ALL remains poor, age-adapted treatment results in CR rates similar to those achieved in younger adults. If higher doses of chemotherapy can be safely administered in the elderly when
Figure 4
Disease-free survival in 34 complete responders. Median DFS is 427 days. Two-year DFS = 16%.
growth factors are systematically used remains to be demon- 
